http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101744398-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0046 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C13-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C13-60 |
| filingDate | 2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101744398-B1 |
| titleOfInvention | Novel phenanthrene-ruthenium compound and parmaceutical composition for preventing or treating cancer comprising the same |
| abstract | The present invention relates to a novel phenanthrene-ruthenium compound and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of cancer. The phenanthrene-ruthenium compound inhibits the Akt-mTOR signal pathway in cancer cells, , It was found that it exhibited excellent anticancer activity which inhibits the proliferation of cancer cells by activating the self-digestive action of cancer cells and inducing apoptosis cell death, and showed excellent anticancer activity even at lower concentrations than conventional anticancer drugs, The phenanthrene-ruthenium compound of the present invention can be usefully used for the prevention or treatment of cancer diseases. |
| priorityDate | 2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.